Thiorphan Shows Promise for Spinal Cord Injury Treatment in Breakthrough UC San Diego Study
核心洞察
UC San Diego researchers identified Thiorphan, an existing drug approved for diarrhea treatment, as a potential therapy for spinal cord injuries using advanced bioinformatics analysis.
The drug demonstrated the ability to stimulate nerve regrowth in human neurons (搜索) grown in laboratory conditions and improved motor function by 50% in rat models with spinal cord injuries.
When combined with neural stem cell transplants, recovery rates doubled in animal studies, suggesting a multi-pronged approach could be key to effective spinal cord repair.
Researchers at the University of California San Diego have identified Thiorphan, an existing drug approved for treating acute infectious diarrhea (搜索), as a promising candidate for treating spinal cord injuries. The breakthrough study, published in Nature on October 29, demonstrates the drug's ability to promote neural regeneration and restore motor function in animal models, offering new hope for patients with paralysis (搜索).
Computational Discovery Reveals Neural Regeneration Potential
The UCSD team, led by neuroscientist Erna van Niekerk, Ph.D., and Professor Mark H. Tuszynski, used advanced bioinformatics tools to identify Thiorphan's regenerative properties. Through a technique called connectivity mapping, researchers analyzed how genes behave during nerve regeneration and cross-referenced these patterns with known drugs.
"The team used a technique called connectivity mapping, building on previous work characterizing neurons (搜索) after an injury that have not been treated with anything," according to the research published in Nature. After spinal cord injury (搜索), neurons naturally revert to an embryonic state more amenable to regeneration. The researchers looked for drugs that prompted similar gene expression effects, eventually identifying Thiorphan as a top candidate.
Thiorphan is the active metabolite of racecadotril, a drug approved and available across several continents—though not in the United States—for treating acute infectious diarrhea (搜索). The compound triggered a gene activation profile associated with nerve repair, making it an ideal candidate for repurposing.
Laboratory Validation in Human Neural Tissue
A major breakthrough came when scientists successfully grew adult human brain cells in laboratory conditions, a notoriously difficult task. When exposed to Thiorphan, these neurons (搜索) displayed enhanced neurite outgrowth—the process by which nerve fibers extend and reconnect. This provided direct evidence that the drug could stimulate regenerative processes in human neural tissue, not just animal cells.
The research team then validated their findings in rat models with spinal cord injuries. The results were striking: treated animals showed a 50% improvement in fine motor function. When Thiorphan was combined with neural stem cell transplants, recovery rates doubled, suggesting that a multi-pronged approach could be key to effective spinal cord repair.
Addressing the Regeneration Challenge
Spinal cord injuries present unique challenges because the central nervous system, unlike the peripheral nervous system, has limited ability to repair itself after injury. As van Niekerk explains, "It really doesn't matter how much you try to elicit regeneration from the neuron if you don't provide a way for these pathways to talk to each other above and below the lesion."
The team addressed this problem using a technique they first published in 2016, employing grafts of neural progenitor cells (搜索) to fill the gap left by severed axons. In the rat model, the combination of Thiorphan injection into the brain and these grafts successfully restored motor function after injury.
Samuel I. Stupp, who studies spinal cord repair at Northwestern University and was not involved with the research, agrees that this approach would likely need to be used in conjunction with other measures. "A spinal cord injury (搜索) is a complex situation, and I don't believe that is going to be solved by just the magic molecule," he noted.
Clinical Development Pathway
The potential treatment still faces several hurdles before reaching human trials. Thiorphan does not cross the blood-brain barrier, and van Niekerk says the laboratory is searching for analogs that can accomplish this crucial step. However, the drug's existing safety record in humans for other indications could accelerate the clinical development process.
"Since thiorphan is a known entity that has been approved as a drug in other regions, there may be more confidence in its safety, which could accelerate the clinical-development process," van Niekerk noted.
This research represents a paradigm shift in neurological repair, blending AI-driven bioinformatics, gene sequencing, and regenerative cell therapy. The approach of repurposing existing drugs using modern computational tools offers a faster, more efficient model for drug discovery compared to developing compounds from scratch.
"Neuron repair is now a realistic scientific goal. It is not a distant hope, and this study proves that with the right drug, the right adult human neurons (搜索) can regenerate again," van Niekerk concluded.